This week's Houston innovators to know includes Sola Lawal of Nuro, Jose Diaz-Gomez of CHI St. Luke's Health, and Kimberly Baker of UT School of Public Health. Courtesy photos

Editor's note: A key attribute of innovators and inventors is the ability to look forward — to see the need for their innovation and the difference it will make. Each of this week's innovators to know have that skill, whether it's predicting the rise of autonomous vehicles or seeing the future of health care.

Sola Lawal, product operations manager at Nuro

Autonomous vehicle delivery service is driving access to food in Houston’s vulnerable communities

Native Houstonian Sola Lawal is looking into how AI and robotics can help increase access to fresh foods in local food deserts. Photo courtesy of Nuro

Sola Lawal has always found himself back in his hometown of Houston. Now working for artificial intelligence and robotics company, Nuro, he sees the potential Houston has to become a major market for autonomous vehicles.

"I think that autonomous vehicles are going to become an industry in the same way your standard vehicles are," Lawal says."One really strong way the Houston ecosystem and Nuro can partner is essentially building out the ancillary."

Lawal shared more on how Houston and Nuro can work together on this week's episode of the Houston innovators podcast. Read more and stream the episode.

Jose Diaz-Gomez, an anesthesiologist at CHI St. Luke's Health

CHI St. Luke's Health has invested in around 40 of the Butterfly iQ devices that can be used to provide accurate and portable ultrasonography on COVID-19 patients. Photo courtesy of CHI St. Luke's

A new, portable ultrasound device has equipped Jose Diaz-Gomez and his team with a reliable, easy-to-use tool for diagnostics and tracking progress of COVID-19 patients. And this tool will continue to help Diaz-Gomez lead his team of physicians.

"Whatever we will face after the pandemic, many physicians will be able to predict more objectively when a patient is deteriorating from acute respiratory failure," he says. "Without this innovation, we wouldn't have been able to be at higher standards with ultrasonography." Read more.

Kimberly A. Baker, assistant professor at UTHealth School of Public Health

UTHealth School of Public Health launched its Own Every Piece campaign to promote women's health access and education. Photo courtesy of Own Every Piece

It was unnerving to Kimberly Baker that proper sex education wasn't in the curriculum of Texas schools, and women were left without resources for contraceptives. So, along with UTHealth School of Public Health, she launched its Own Every Piece campaign as a way to empower women with information on birth control and ensure access to contraceptive care regardless of age, race, relationship status or socioeconomic status.

"You feel like the campaign is talking to you as a friend, not talking down to you as an authority or in any type of shaming way," says Kimberly A. Baker, assistant professor at UTHealth School of Public Health. One of her favorite areas of the website is the "Find a Clinic" page, connecting teens and adult women to nearby clinics, because "one of the biggest complaints from women is that they didn't know where to go," says Baker. Continue reading.

UTHealth School of Public Health launched its Own Every Piece campaign to promote women's health access and education. Photo courtesy of Own Every Piece

This Houston organization is rethinking access to and education on women's health

women's health

If you browse through the required school curriculum in Texas, you might be surprised to find that sex ed doesn't quite make the cut. Sex education is optional in the Lone Star State and state law requires schools to stress abstinence when choosing to teach the subject, which can make understanding birth control even more confusing for both teens and adult women.

UTHealth School of Public Health launched its Own Every Piece campaign as a way to empower women with information on birth control and ensure access to contraceptive care regardless of age, race, relationship status or socioeconomic status. One click to the Own Every Piece website and you'll be greeted by the smiles of diverse women, along with videos of their birth control journey and educational information on various birth control options.

"You feel like the campaign is talking to you as a friend, not talking down to you as an authority or in any type of shaming way," says Kimberly A. Baker, assistant professor at UTHealth School of Public Health. One of her favorite areas of the website is the "Find a Clinic" page, connecting teens and adult women to nearby clinics, because "one of the biggest complaints from women is that they didn't know where to go," says Baker.

The website and social media platforms preach of body-positivity, empowerment, and knowledge. Prompts from a "true or false"-style quiz debunk myths from birth control weight gain to proper condom use on the home page. In the name of inclusivity, women can even upload their own birth control story to share with Own Every Piece's audience.

Baker and her team got their start in school districts developing programs for middle and high schoolers while also training teachers on how to discuss birth control openly. After working in over 20 school districts with the goal of preventing teen pregnancy through education, Baker identified a new problem: the significant lack of access to health care within the Houston community.

"We wanted to figure out what the major gaps were," Baker says. "What we found, of course, was how expensive birth control was — especially with some of the most effective methods."

Kimberly A. Baker is assistant professor at UTHealth School of Public Health. Photo courtesy of Own Every Piece

Let's crunch some numbers. When interpreting the price of contraceptives, the type of birth control and access to health care can impact how much women pay out-of-pocket. According to Baker, the standard pill can cost anywhere from $10 to $30 a month while implanting long-acting reversible contraceptives like the IUD can cost upwards of $600 to $700. These calculations don't factor in the cost of a doctor's appointment, the removal of a device like the IUD, or even the average $4,500 it costs to give birth if you choose to have a child in the U.S.

After noticing gaps in who could pay for service, Baker and her team realized that some community centers didn't have the funds to have long-acting contraceptive on hand.

"We knew if we partnered with health clinics and health centers to help train them to better serve folks that they weren't serving well, and to give them more funds to buy methods that women couldn't probably afford...we would be filling that gap," she says.

Creating comfort and trust among women looking for contraceptives was another key intention in the campaign's launch.

"When [women] enter a community health clinic, they should feel confident to ask questions and to know that they're receiving all the accurate information they should be getting so they can make the best decision for them," says Baker.

Baker likes to think of the Own Every Piece project as a "more celebratory campaign around birth control that we hadn't seen before," she says. "There are so many stereotypes around sexuality and reproduction that are very shame-based," says Baker, particularly for "Latinx and Black women."

She acknowledges how epithetical birth control messaging that suggests women shouldn't "have more kids" or implies "pregnancy is a bad thing" frames reproductive health in a negative way. "We wanted a campaign that let women know that they own their body. They make decisions about their body, and birth control is a piece of that," she says.

The purpose of providing access took on a new meaning when the coronavirus hit. Since Own Every Piece began as a digital campaign targeted to Houston women ages 18 to 30, the initiative had a head start in the race to move online.

"We saw an opportunity to figure out how we can tell our community health centers to get into the telecontraception space because we've already established trust virtually through our campaign," explains Baker.

Prior to the COVID-19 pandemic, Texas held the title of the state with the most uninsured residents in the U.S. In a state with 2.9 million unemployment claims since March, access to affordable birth control has never been more essential for women.

"From women who lost their insurance due to losing their job because of COVID-19, this has been a godsend," says Baker.

Telemedicine has also added convenience for women who didn't have the time to check out a clinic in-person before the pandemic.

While COVID-19's strains on American health care continue to dominate headlines, birth control has also managed to make national news. On July 8, the Supreme Court ruled that employers can opt-out of birth control coverage—a decision that could result in an estimated 126,000 women losing contraceptive coverage from their employers, according to the New York Times.

The 7-to-2 Supreme Court decision is the latest in a seven-year-long litigation over religious objections to birth control. Outside of pregnancy prevention, birth control helps women cope with premenstrual dysmorphic disorder, polycystic ovarian syndrome, endometriosis, acne, and a number of other issues.

"We have to work harder to have inclusive messaging around [birth control usage], because birth control isn't just about pregnancy prevention," explains Baker. "People use birth control for a number of needs. When you message it just around pregnancy prevention, people start to feel like something is wrong with being pregnant, and that's not what we set out to do."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”